Issue Date: August 24, 2009
FDA Clears Schering Antipsychotic Drug
FDA has approved Schering-Plough's antipsychotic drug, Saphris, for acute treatment of schizophrenia in adults and for episodes associated with severe bipolar-1 disorder. The drug will compete with Johnson & Johnson's Risperdal, Bristol-Myers Squibb's Abilify, and Eli Lilly & Co.'s Zyprexa. Schering, which is being acquired by Merck & Co., projects sales of Saphris to exceed $1 billion per year. Schering acquired the drug when it purchased Organon BioSciences in 2007.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society